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The Nematode Death
Machine in 3D
Regulated apoptosis is part of the development of the
nematode Caenorhabditis elegans. In a recent paper
in Nature, Yan et al. (2005) describe the in vitro recon-
stitution of the core components of the worm apo-
ptotic pathway. Based on a structural analysis of the
complex between the death activator CED-4 and the
antiapoptotic protein CED-9, the authors explain
the regulation of activity of CED-4. Intriguingly, CED-4
comprises a AAA+ type ATPase domain yet does not
seem to need ATP hydrolysis for activity.
All cells destined to die during the development of a
mature worm use a common cell-death pathway (Hor-
vitz, 2003). This pathway, initially characterized geneti-
cally, requires the sequential participation of the pro-
teins EGL-1, CED-4, and CED-3. These “killer proteins”
are under negative regulation by the “protector protein”
CED-9. However, biochemical analysis has only given
limited snapshots of the molecular basis of this path-
way. In a recent paper in Nature, Yan and colleagues
(2005) reconstituted the nematode apoptotic pathway
from its basic components and provided an atomic
level structure of a complex of CED-4 and CED-9. This
complex is a key point of regulation in the apoptotic
signaling cascade. The picture that now emerges bears
a significant resemblance to the core death pathway in
humans (Boatright and Salvesen, 2003) but also deliv-
ers some surprises.
The objective of the apoptotic pathway in all multicel-
lular animals is to activate a protease. In nematodes,
this protease is CED-3 and in humans it is the distant
homolog caspase-9. In both species, the protein that
activates CED-3—CED-4 in nematodes and Apaf-1 in
humans—is present in a latent conformation awaiting
activation signals. CED-4 uses a distinct protein, the
protector CED-9, to ensure latency, whereas the pre-
sumably more evolved Apaf-1 contains its own inhibi-
tory domain. By solving the structure of the CED-9/
CED-4 complex at 2.7 Å resolution, Yan and coworkers
(2005) elucidate the mechanism of latency of the nema-
tode CED-4 protease. In this complex, CED-4 is an
asymmetric dimer, with one subunit in contact with the
protector, CED-9. In the absence of CED-9, CED-4
forms a homotetramer, as judged by gel filtration and
electron microscopy. In short, CED-9 occupies the po-
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atential interaction sites for the dimer to tetramer transi-
tion of CED-4. Formation of a tetramer activates CED-4,
which drives the activation of the protease CED-3. In
this scenario, the job of the upstream “killer” protein
EGL-1 is to bind to and displace the protector, CED-9,
thereby allowing the activator, CED-4, to form tetramers
spontaneously (see Figure 1). This is consistent with
the comparison of the structure of CED-4/CED-9 with
the previously reported structure of CED-9/EGL-1 (Yan
t al., 2004).
By using all purified components, the authors recon-
tituted the essential aspects of this process: the acti-
ation of CED-3 by CED-4 and the inhibition of this acti-
ation by the CED-9. Furthermore, they showed that
ddition of EGL-1 to CED-4, inhibited by being in a
omplex with CED-9, caused an activation of CED-3 by
ED-4. They proceeded to confirm some of the struc-
ural predictions by constructing mutants of the individ-
al components and testing these mutants in vitro and
n vivo.
At first glance, the mechanism of activation of CED-4
n the nematode appears similar to that of Apaf-1 in
umans. The activator Apaf-1 is also driven into an oligo-
er that activates caspase-9, although in humans, the
apoptosome” forms heptamers, unlike the nematode
ED-4 which forms tetramers (Acehan et al., 2002). The
ifferences come to light when one looks at the signals
equired to turn on the activator. In nematodes, EGL-1
isplaces CED-9 from CED-4, but in humans the Apaf-1
utoinhibitory domain is displaced by cytochrome C (Li
t al., 1997). What is particularly unusual about this dif-
erence is that the EGL-1 and the CED-9 counterparts
n humans (the Bid family and the Bcl-2 family, respec-
ively) act far upstream of Apaf-1, apparently regulating
he release of pro-apoptotic proteins from mitochon-
ria, although using a very similar binding geometry.
his radical divergence of function of Bcl-2 family
embers between nematodes and humans remains a
entral enigma in understanding apoptosis.
The apoptotic activation complex seems to fulfill the
riteria for a cellular machine. It contains several dis-
inct components, it is likely to require energy, and it
elivers a predictable outcome (Alberts, 1998). If one
ccepts the concept of conservation of mechanism in
iology, then similar cellular machines that perform
nalogous functions should use comparable mecha-
isms. Here again, there seems to be differences be-
ween the human and nematode apoptosomes. The
tomic resolution structure of latent Apaf-1 reveals an
nternally bound molecule of ADP that provides interac-
ions to help stabilize this form (although there are
vailable interactions for ATP to replace ADP) (Riedl et
l., 2005). ATP addition and hydrolysis are required to
rive full assembly and activation of Apaf-1 and subse-
uent activation of caspase-9. Thus the driving force
ay not be strictly ATP hydrolysis alone but rather
DP/ATP nucleotide exchange, as proposed in a recent
aper describing the 12.8 Å resolution of the apo-
tosome (Yu et al., 2005). In contrast, both the latent
nd oligomer forms of CED-4 contain ATP, and no ATP
ydrolysis or nucleotide exchange is reported (Yan et
l., 2005).
The nucleotide oligomerization domains of CED-4
nd Apaf-1 are structurally related to the AAA+ family
f ATPases (ATPases associated with various cellular
ctivities) that are able to induce conformational changes
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193Figure 1. Comparison of the Activation of the Nematode and Human Apoptosomes
Yan and colleagues (2005) propose that the nematode activator of CED-3, the CED-4 dimer, simply requires removal of the protector CED-9
by EGL-1. Thus the AAA+ domain of CED-4 may be a divergent ATPase that has dispensed with nucleotide hydrolysis and exchange.
Alternatively, nucleotide exchange may have occurred upstream of the formation of the CED-4/CED-9 complex, possibly in the transition from
a putative monomeric CED-4 to its dimeric form, which partners with CED-9. The autoinhibited human activator Apaf-1 requires nucleotide
exchange, ATP hydrolysis, and cytochrome C to assemble into an active oligomeric complex. Once assembled, the oligomeric apoptosomes
activate their respective proteases.in their target proteins (Leipe et al., 2004). Defining fea-
tures of the AAA+ ATPase domain are its ability to as-
semble into oligomeric rings and couple cycles of nu-
cleotide binding and hydrolysis to produce protein
conformational changes (Hanson and Whiteheart, 2005).
In fact, several years ago, Jaroszewski and colleagues
made a bold prediction that the nucleotide oligomeriza-
tion domains of CED-4 and Apaf-1 would use an ATP-
driven mechanism to form oligomeric protease activa-
tor platforms (Jaroszewski et al., 2000). This model has
been confirmed recently through crystal structures and
structures from cryoelectron microscopy (Riedl et al.,
2005; Yan et al., 2005; Yu et al., 2005). However, the lack
of evidence for nucleotide exchange in Apaf-1 and the
lack of support for ATP hydrolysis or nucleotide ex-
change in CED-4 clearly distinguishes this group of
AAA+ proteins from the other members of this family.
Either we are missing evidence for nucleotide ex-
change and hydrolysis, or CED-4 has diverged from the
conformational cycling function of AAA+ proteins.
Finally, through recent structural descriptions of apo-
ptotic platforms, the field is now in possession of an
abundance of fresh evidence for how the protease acti-
vators are released from latency in humans and nema-
todes. Now it is time to answer the open question
posed at the end of these seminal reports: How is the
oligomerization of these activators coupled to the pro-
teolytic activation of the killer proteases CED-3 and
caspase-9? Is it simply by causing dimerization of the
protease zymogens, as seen in vitro (Boatright and
Salvesen, 2003), or is there another mechanism?Cristina Pop and Guy S. Salvesen
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